Pacific Biosciences of California Inc expected to post a loss of 33 cents a share - Earnings Preview

Pacific Biosciences of California

28/10/2023 02:34

* Pacific Biosciences of California Inc  PACB.OQ 
 PACB.O  is
expected to show a rise in quarterly revenue when it reports 
results 
    * The Menlo Park California-based  company is expected to
report 
a 50.9% increase in revenue to $48.761 million from $32.31
million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Pacific Biosciences
of
California Inc is for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pacific
Biosciences of California Inc is $13​, above​ its last closing
price of $7.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.32       -0.32      -0.28     Beat    12.7
 Mar. 31 2023  -0.33       -0.33      -0.36     Missed  -8.3
 Dec. 31 2022  -0.37       -0.36      -0.37     Missed  -2.4​
 Sep. 30 2022  -0.33       -0.33      -0.34     Missed  -2.5
 ​​Jun.        -0.32       -0.32      -0.32     Met     1
 30 2022                                                
 Mar. 31 2022  -0.31       -0.31      -0.37     Missed  -20​
 Dec. 31 2021  -0.28       -0.28      -0.31     Missed  -9.4
 Sep. 30 2021  -0.22       -0.22      -0.23     Missed  -5.7
 This summary was machine generated October 28 at 01:34 GMT.  All
figures in US dollars  unless otherwise stated